Large Scale Biology Corporation Acquires License for Development of Atherosclerosis Therapeutic.

Business Editors/Health/Medical Writers

VACAVILLE, Calif.--(BUSINESS WIRE)--Nov. 18, 2003

Large Scale Biology Corporation (Nasdaq:LSBC) today announced a new addition to its product pipeline, an exclusive license agreement with the Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio for the development of a drug to treat atherosclerosis, a leading cause of death in the U.S.

LSBC's license covers atherosclerosis and cholesterol storage disorders discussed in an article co-authored by Gregory A. Grabowksi, MD and published last Friday in the American Heart Association journal Arteriosclerosis, Thrombosis and Vascular Biology, (http://atvb.ahajournals.org/atvbefirst.shtml), Volume 23, Issue 11. Promising results in mouse models indicate that administration of lysosomal acid lipase (LAL) decreases atherosclerotic plaque accumulation in mice chronically fed high fat diets. Coronary and aortic plaque were eliminated in early stages and reduced both quantitatively and qualitatively in advanced stages. Dr Grabowski, Professor and Director of the Division of Human Genetics at Cincinnati Children's, called the results "extremely encouraging for the development of a pharmaceutical that can have an important impact on the treatment of a major cardiac health problem throughout the world."

Noting that "there is potential to treat both atherosclerosis and cholesterol storage disorders," Kevin J. Ryan, President and CEO of LSBC called the collaboration "an outstanding new addition to the LSBC commercial development portfolio." Sales of cardiac therapeutic drugs in the U.S. alone range in the billions of dollars annually. According to the American Heart Association, coronary heart disease (CHD) is the most common form of heart disease and the leading cause of death for Americans. About 12.9 million living Americans have a history of heart attack, angina pectoris or both. Each year, an estimated 1.1 million Americans suffer a heart attack, about 515,000 of which are fatal.

LSBC will employ its proprietary technologies to produce LAL for clinical applications and will be seeking a commercial partner for the co-development of the drug. Financial details of the agreement between LSBC and Cincinnati Children's were not disclosed.

About Cincinnati Children's Hospital Medical Center

Cincinnati Children's Hospital Medical Center is a 373-bed institution dedicated to the pursuit of perfect health care. It is the only pediatric organization in the United States to receive the prestigious Pursuing Perfection grant from the Robert Wood Johnson Foundation. The Cincinnati Children's Research Foundation ranks third nationally among all pediatric centers in research grants from the National Institutes of Health. The Cincinnati Children's vision is to be the leader in improving child health, through patient care, research and education. Additional information about Cincinnati Children's can be found at www.cincinnatichildrens.org.

About Large Scale Biology Corporation

Large Scale Biology uses its biomanufacturing, functional genomics and proteomics technologies to develop and manufacture drugs and vaccines for effective treatment of disease. Corporate offices, the Genomics Division and Biopharmaceutical Development laboratories are headquartered in Vacaville, California; the Company's Proteomics Division is located in Germantown, Maryland; and the Company's commercial-scale biomanufacturing facility is located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com http://www.lsbc.com.

This release contains forward-looking statements about an application of LSBC's technologies and the market for one of our products under development. These forward-looking statements involve risks, uncertainties and situations that may cause our actual results to differ materially from those implied by these statements, including our ability to produce adequate quantities of product, the ability of our collaborators to generate demand for products we make for them, the effectiveness of our and our collaborators' technologies to produce specific therapeutic products and/or in a cost-effective manner, any difficulties or delays in obtaining regulatory approval to test and market such products, and the requirement of substantial funding for us to preserve our technology base and product pipeline. We cannot guarantee future results. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this release. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities and Exchange Commission, including our reports on Forms 10-K and 10-Q. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Note to Editors: LSBC(TM) is a trademark of Large Scale Biology Corporation.